Elsaid cleverly utilized a zebrafish model that does not produce GB3 to investigate other potential therapeutic targets for Fabry disease, particularly the implications of the Sod2(superoxide dismutase 2) activity mechanism [43]. This evidence concerns the gene SOD2 and Fabry disease.